JHS Svendgaard Laboratories Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹2.72Overvalued by 66.75%vs CMP ₹8.18

P/E (15.0) × ROE (1.1%) × BV (₹20.00) × DY (2.00%)

Defaults: P/E=15

₹7.23Overvalued by 11.61%vs CMP ₹8.18
MoS: -13.1% (Negative)Confidence: 40/100 (Low)Models: 2 Under, 3 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹2.7234%Over (-66.7%)
Net Asset ValueAssets₹19.6620%Under (+140.3%)
EV/EBITDAEnterprise₹2.7617%Over (-66.3%)
ROCE CapitalReturns₹1.9014%Over (-76.8%)
Revenue MultipleRevenue₹10.3915%Under (+27%)
Consensus (5 models)₹7.23100%Overvalued
Key Drivers: ROE 1.1% is below cost of equity. | Wide model spread (₹2–₹20) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 0.0% · Defaults: P/E=15

*Investments are subject to market risks

Analysis summary

Data coverage: Price-data record updated 24 September 2026, 9:31 pm +05:30. Annual results through Mar 2025; quarterly results through Dec 2025; cash flow through Mar 2026. Each section can have a different reporting period. The share price is not live.

Valuation in context

JHS Svendgaard Laboratories Ltd: the stored intrinsic value estimate is ₹7.23, compared with a stored share price of ₹8.18. The model value is 11.6% below that quote. The model classifies this as overvalued; it is an estimate dependent on the inputs and assumptions, not a price target or a buy/sell recommendation.

Operating performance

Revenue for Mar 2025 was ₹92.00 Cr, versus ₹70.80 Cr in Mar 2024 (29.9% year on year). Net profit for Mar 2025 was ₹-19.74 Cr, versus ₹-4.06 Cr in Mar 2024. These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.

Cash generation

For the same Mar 2025 period, operating cash flow was ₹-5.00 Cr against net profit of ₹-19.74 Cr.A cash-to-profit ratio is not meaningful with zero or negative profit.

Balance-sheet check

Reported borrowings were ₹15.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.

How to use the valuation and peer comparisons

The Intrinsic Value panel combines the available model estimates using the displayed weights. Earnings, cash-flow, dividend and asset-based methods can give very different answers. The displayed 12% cost of equity and 4% terminal growth assumptions apply where relevant; historical EPS growth is not a promise of future growth. Use the individual values and their spread to judge sensitivity.

The peer group follows the stored industry classification and may include different business models. Compare reporting periods, leverage and recurring earnings before interpreting a valuation gap. For banks and other financial businesses, capital adequacy and asset quality can be more informative than industrial-company cash-flow ratios.

Sources: Company data source. Check the company filings linked by the source for the reporting basis and exceptional items.

Automatically generated interpretation of the stored financial data, not a separately researched analyst opinion. Missing data is not evidence of poor performance. New filings become available here after the existing data refresh process captures them.

Investment Snapshot

57
JHS Svendgaard Laboratories Ltd scores 57/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health46/100 · Moderate
ROCE 0.8% WeakROE 1.1% WeakD/E 0.02 Low debtInterest Coverage -2.0x RiskyProfitable 1/5 available years Reported history
Smart Money70/100 · Strong
FII holding up 1.57% (6mo) AccumulatingPromoter holding at 33.9% Stable
Earnings Quality75/100 · Strong
OPM expanding (-6% → -3%) ImprovingWorking capital: 48 days (improving) Efficient
Quarterly Momentum70/100 · Strong
Revenue (4Q): +6% YoY GrowingOPM: 7.2% (up 6.1% YoY) Margin expansion
Industry Rank25/100 · Weak
ROCE 0.8% vs industry 39.3% Below peersROE 1.1% vs industry 30.7% Below peers3Y sales CAGR: 2% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores use stored reporting periods and are screening indicators, not investment recommendations. Missing health ratios are excluded. Broad industry groups and financial-sector accounting can limit comparability.

Advertisements

Share Price and Basic Stock Data

Last Updated: September 24, 2026, 9:31 pm

Market Cap 72.4 Cr.
Current Price 8.18
Intrinsic Value₹7.31
High / Low 13.9/6.15
Stock P/E
Book Value 20.0
Dividend Yield0.00 %
ROCE0.78 %
ROE1.11 %
Face Value 10.0
PEG Ratio0.00

Understand these figures: how to read the P/E ratio, ROE versus earnings per share, and calculate intrinsic value.

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for JHS Svendgaard Laboratories Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Honasa Consumer Ltd 15,424 Cr. 473 510/24864.6 42.90.63 %18.7 %15.1 % 10.0
Ambica Agarbathies Aroma & Industries Ltd 44.3 Cr. 25.4 29.9/20.013.0 65.60.00 %8.34 %3.11 % 10.0
Ador Multi Products Ltd 102 Cr. 90.0 149/61.0 46.60.00 %7.67 %6.67 % 10.0
Kaya Ltd 477 Cr. 313 484/224 1010.00 %45.6 %% 10.0
Jyothy Labs Ltd 7,077 Cr. 193 325/18819.3 55.81.81 %24.6 %19.0 % 1.00
Industry Average59,166.57 Cr1,413.7950.79110.481.24%39.32%30.74%4.94

All Competitor Stocks of JHS Svendgaard Laboratories Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 22.1921.7215.9018.9314.3021.6624.4819.6822.6625.1723.4522.2823.27
Expenses 24.4125.2818.0218.5214.3620.8222.5120.5222.4130.5521.7921.3721.60
Operating Profit -2.22-3.56-2.120.41-0.060.841.97-0.840.25-5.381.660.911.67
OPM % -10.00%-16.39%-13.33%2.17%-0.42%3.88%8.05%-4.27%1.10%-21.37%7.08%4.08%7.18%
Other Income 0.94-11.540.410.202.341.370.320.860.27-1.441.001.140.59
Interest 0.160.110.130.100.110.130.120.110.130.210.160.200.28
Depreciation 1.461.611.321.501.631.901.971.981.972.021.881.861.90
Profit before tax -2.90-16.82-3.16-0.990.540.180.20-2.07-1.58-9.050.62-0.010.08
Tax % -4.83%-36.39%-18.35%-26.26%100.00%516.67%415.00%398.07%15.82%-23.09%-69.35%1,800.00%-887.50%
Net Profit -2.76-10.71-2.59-0.730.01-0.75-0.63-10.32-1.84-6.961.06-0.200.79
EPS in Rs -0.43-1.65-0.40-0.090.00-0.10-0.08-1.21-0.21-0.810.12-0.020.09

Last Updated: March 4, 2026, 7:16 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 4:16 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 35.2855.1099.62104.18140.29123.99139.11100.7786.2584.8170.8092.0094.17
Expenses 39.0658.9593.1192.45126.34123.89137.4098.8087.0993.8871.7396.0195.31
Operating Profit -3.78-3.856.5111.7313.950.101.711.97-0.84-9.07-0.93-4.01-1.14
OPM % -10.71%-6.99%6.53%11.26%9.94%0.08%1.23%1.95%-0.97%-10.69%-1.31%-4.36%-1.21%
Other Income -2.67-5.79-17.300.3932.035.973.167.499.39-7.314.310.021.29
Interest 14.140.140.360.620.741.031.951.241.390.550.460.570.85
Depreciation 14.7112.3610.496.366.817.098.767.257.056.026.357.957.66
Profit before tax -35.30-22.14-21.645.1438.43-2.05-5.840.970.11-22.95-3.43-12.51-8.36
Tax % -18.39%0.18%0.00%-326.85%32.19%-18.54%-16.95%-39.18%4,000.00%-23.66%18.37%57.87%
Net Profit -28.81-22.18-21.6421.9426.06-1.67-4.861.34-4.29-17.52-4.06-19.74-5.31
EPS in Rs -11.95-9.20-5.764.984.29-0.11-0.330.19-0.620.62-0.52-2.31-0.62
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)23.01%2.43%201.39%18.78%-106.41%-191.02%127.57%-420.15%-308.39%76.83%-386.21%
Change in YoY Net Profit Growth (%)0.00%-20.58%198.95%-182.61%-125.19%-84.61%318.59%-547.72%111.76%385.22%-463.03%

JHS Svendgaard Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:5%
5 Years:-8%
3 Years:2%
TTM:15%
Compounded Profit Growth
10 Years:-2%
5 Years:%
3 Years:%
TTM:-624%
Stock Price CAGR
10 Years:0%
5 Years:-9%
3 Years:-23%
1 Year:-61%
Return on Equity
10 Years:2%
5 Years:0%
3 Years:0%
Last Year:-11%

Last Updated: September 5, 2025, 8:15 am

Advertisements

Balance Sheet

Last Updated: July 3, 2026, 6:30 am

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital 243844616161646578788687
Reserves 96639011311611712412195918787
Borrowings 19322797635615
Other Liabilities 331919323955333052222526
Total Liabilities 171122155208223241228222228197204215
Fixed Assets 1086565717166635965909089
CWIP 0111579209104
Investments 00118106243345
Other Assets 635789118137163154140152102110117
Total Assets 171122155208223241228222228197204215

Reserves and Borrowings Chart

Cash Flow

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity + 7-4-414-111012-923-9-5-3
Cash from Investing Activity + 11-3-27-7-11-2-510-21-20-12
Cash from Financing Activity + -104101413010-2-122311
Net Cash Flow -1230-5-020-1632-28-2-3
Free Cash Flow 9-7-173-2605-1621-33-14-15
CFO/OP -189%-58%-33%119%-10,000%595%650%1,051%-257%1,001%122%-77%

Free Cash Flow

Free cash flow reported in the stored cash-flow statement (₹ Cr)
PeriodMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Free Cash Flow9.00-7.00-17.003.00-26.000.005.00-16.0021.00-33.00-14.00-15.00

This table and the chart use the Free Cash Flow row from the same stored cash-flow statement. Free cash flow generally measures operating cash flow after capital expenditure; check the source definition and reporting basis. It is not operating profit minus borrowings.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 188167254811115825221377806652
Inventory Days 12294539565603097114128176153
Days Payable 9510667123153134177128130197197141
Cash Conversion Cycle 2151561219238510518261114663
Working Capital Days -708-395856122173198272217415148
ROCE %-10%-12%-3%5%8%-0%4%1%1%-2%-2%-5%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters 37.73%37.73%37.73%37.73%34.56%34.56%34.56%34.56%34.56%34.56%33.85%33.85%
FIIs 0.00%0.00%2.29%0.15%1.69%1.59%1.60%1.59%1.57%1.57%3.60%3.14%
DIIs 0.00%9.16%6.21%6.05%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public 62.25%53.10%53.75%56.05%63.76%63.85%63.84%63.86%63.87%63.86%62.57%63.03%
No. of Shareholders 22,79422,64826,44825,76825,99426,27625,56725,15525,00725,15125,33025,150

Shareholding Pattern Chart

No. of Shareholders

JHS Svendgaard Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) -2.37-0.52-2.34-0.630.20
Diluted EPS (Rs.) -2.37-0.52-2.34-0.630.20
Cash EPS (Rs.) -1.380.29-1.430.421.33
Book Value[Excl.RevalReserv]/Share (Rs.) 20.1821.6727.7830.0530.74
Book Value[Incl.RevalReserv]/Share (Rs.) 20.1821.6727.7830.0530.74
Revenue From Operations / Share (Rs.) 10.759.0314.8213.2915.65
PBDIT / Share (Rs.) -0.130.430.811.321.47
PBIT / Share (Rs.) -1.06-0.37-0.330.230.34
PBT / Share (Rs.) -1.46-0.43-3.370.010.15
Net Profit / Share (Rs.) -2.31-0.51-2.58-0.660.20
NP After MI And SOA / Share (Rs.) -2.31-0.51-2.38-0.620.18
PBDIT Margin (%) -1.234.775.509.919.39
PBIT Margin (%) -9.87-4.19-2.251.732.19
PBT Margin (%) -13.59-4.84-22.700.110.96
Net Profit Margin (%) -21.46-5.73-17.43-4.971.33
NP After MI And SOA Margin (%) -21.46-5.73-16.07-4.691.18
Return on Networth / Equity (%) -11.43-2.38-8.96-2.170.63
Return on Capital Employeed (%) -5.14-1.70-1.090.731.07
Return On Assets (%) -9.81-2.05-6.54-1.820.52
Total Debt / Equity (X) 0.020.020.000.000.00
Asset Turnover Ratio (%) 0.460.320.410.360.42
Current Ratio (X) 2.181.872.364.185.23
Quick Ratio (X) 1.701.332.003.544.73
Inventory Turnover Ratio (X) 7.503.114.365.168.94
Interest Coverage Ratio (X) -2.017.345.096.137.63
Interest Coverage Ratio (Post Tax) (X) -28.88-7.822.78-2.082.08
Enterprise Value (Cr.) 81.22121.6970.51136.74117.07
EV / Net Operating Revenue (X) 0.881.720.731.591.16
EV / EBITDA (X) -71.6836.0313.3115.9912.37
MarketCap / Net Operating Revenue (X) 1.041.811.061.551.27
Price / BV (X) 0.550.750.590.710.68
Price / Net Operating Revenue (X) 1.041.811.061.551.27
EarningsYield -0.20-0.03-0.15-0.030.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Frequently asked questions

What is the intrinsic value of JHS Svendgaard Laboratories Ltd and is it undervalued?

JHS Svendgaard Laboratories Ltd: the stored intrinsic value estimate is ₹7.23, compared with a stored share price of ₹8.18. The model value is 11.6% below that quote. The model classifies this as overvalued; it is an estimate dependent on the inputs and assumptions, not a price target or a buy/sell recommendation. The estimate uses the available valuation models and weights shown in the Intrinsic Value panel, including earnings, cash-flow and asset-based approaches where data permits. It is not a P/E-only calculation.

What share price and 52-week range are shown for JHS Svendgaard Laboratories Ltd?

The stored share price is ₹8.18. Price-data record updated: 24 September 2026, 9:31 pm +05:30. This is not a live quote. The stored 52-week high / low is 13.9/6.15; this is a rolling range, not a financial-year range.

How have JHS Svendgaard Laboratories Ltd's revenue and profit changed?

Revenue for Mar 2025 was ₹92.00 Cr, versus ₹70.80 Cr in Mar 2024 (29.9% year on year). Net profit for Mar 2025 was ₹-19.74 Cr, versus ₹-4.06 Cr in Mar 2024. These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.

Does JHS Svendgaard Laboratories Ltd's profit convert into cash?

For the same Mar 2025 period, operating cash flow was ₹-5.00 Cr against net profit of ₹-19.74 Cr.A cash-to-profit ratio is not meaningful with zero or negative profit.

What should I check in JHS Svendgaard Laboratories Ltd's balance sheet?

Reported borrowings were ₹15.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.

What could change JHS Svendgaard Laboratories Ltd's intrinsic value estimate?

Changes in sustainable earnings, cash generation, capital needs, debt and share count can change the estimate. The displayed model uses a 12% cost of equity and 4% terminal growth assumption where applicable. Higher discount rates or weaker growth generally reduce discounted values. Compare the individual model values and weights, and verify fresh filings before relying on the result.

Advertisements
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in JHS Svendgaard Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE